Hormone blocker trial aims to unlock secrets of cervical mucus
NCT ID NCT07111247
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how a hormone-blocking drug called Relugolix affects cervical mucus in healthy women. Fifteen participants will take the drug for 10 days, and researchers will collect samples of blood, mucus, and tissue at different times. The goal is to better understand how mucus changes during the menstrual cycle, which could help with fertility or contraception research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Relugolix (a hormone blocker)
- What this could lead to
- If successful, this could improve understanding of cervical mucus, potentially aiding fertility or contraception research.
- What could go wrong
- This is a very small, early-phase study with only 15 participants, so results may not apply broadly. It is designed to gather knowledge, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL MUCUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.